Masahiko Ando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masahiko Ando has a total of 383 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Tamakoshi
Department of Public Health, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
5 shared publications - Kenji Wakai
Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
5 shared publications - Masahiro Nakatochi
Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan
5 shared publications - Shigekazu Ukawa
Osaka Metropolitan University Graduate School of Human Life and Ecology
5 shared publications Shun-Ichi Isa
Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan
5 shared publicationsYachiyo Kuwatsuka
Nagoya Univ, Dept Adv Med, Grad Sch Med, 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi, Japan
5 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
A multicenter randomized phase III trial comparing MET tyrosine kinase inhibitors versus immune checkpoint inhibitors with or without chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations: JCOG2506 (DECIDE-MET)
- 7 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA multicenter randomized phase III trial comparing MET tyrosine kinase inhibitors versus immune checkpoint inhibitors with or without chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations: JCOG2506 (DECIDE-MET)
- 1 June 2025
- Published by Human Kinetics in Journal of Physical Activity and Health
- Vol. 22 (6) , 706-715
Effects of Weight-Bearing Resistance Training With Explosive Motions on the Rate of Force Development in Community-Dwelling Older Adults: A Randomized Controlled Trial
Background: Eliminating risk factors for falls leads to reduction of the incidence of frailty. The recommended training program used only body weight resistance and no equipment to prepare for quick movements in daily living in community-dwelling older adults is unknown. Thus, we compared the effects of weight-bearing resistance training with (WEM) and without explosive motions (WOEM). Methods: Sixty older adults were randomly assigned to WEM and WOEM groups. The WEM group performed the concentric phase during repetitions quickly and the WOEM group performed it at traditional velocity. The designated training programs consisted of 8 events to train the whole body for 50 minutes twice a week for 12 weeks. The changes in the rate of force development of toe grip, single knee extension, and flexion from baseline to 12 weeks were measured. Between-group differences were analyzed for changes in each outcome variable. Results: Twenty-seven participants in the WEM group (70 [5] y) and 21 participants in the WOEM group (69 [4] y) completed the study. The change in the early rate of force development of toe grip from baseline to 12 weeks was significantly greater in the WEM group (0–30 ms: effect size = 0.53, 95% CI = 6.36–68.10, P = .049; 0–50 ms: effect size = 0.56, CI = 10.05–86.02, P = .046) than in the WOEM group. Conclusions: Weight-bearing resistance training with explosive motions has the advantage of not being limited to tools and places. Therefore, it is more suitable than traditional repetition velocity training for quick movement by increasing rate of force development in community-dwelling older adults before they become frail.
- 1 June 2025
- Published by Human Kinetics in Journal of Physical Activity and Health
- Vol. 22 (6) , 706-715
Effects of Weight-Bearing Resistance Training With Explosive Motions on the Rate of Force Development in Community-Dwelling Older Adults: A Randomized Controlled Trial
Background: Eliminating risk factors for falls leads to reduction of the incidence of frailty. The recommended training program used only body weight resistance and no equipment to prepare for quick movements in daily living in community-dwelling older adults is unknown. Thus, we compared the effects of weight-bearing resistance training with (WEM) and without explosive motions (WOEM). Methods: Sixty older adults were randomly assigned to WEM and WOEM groups. The WEM group performed the concentric phase during repetitions quickly and the WOEM group performed it at traditional velocity. The designated training programs consisted of 8 events to train the whole body for 50 minutes twice a week for 12 weeks. The changes in the rate of force development of toe grip, single knee extension, and flexion from baseline to 12 weeks were measured. Between-group differences were analyzed for changes in each outcome variable. Results: Twenty-seven participants in the WEM group (70 [5] y) and 21 participants in the WOEM group (69 [4] y) completed the study. The change in the early rate of force development of toe grip from baseline to 12 weeks was significantly greater in the WEM group (0–30 ms: effect size = 0.53, 95% CI = 6.36–68.10, P = .049; 0–50 ms: effect size = 0.56, CI = 10.05–86.02, P = .046) than in the WOEM group. Conclusions: Weight-bearing resistance training with explosive motions has the advantage of not being limited to tools and places. Therefore, it is more suitable than traditional repetition velocity training for quick movement by increasing rate of force development in community-dwelling older adults before they become frail.
- Open Access
The Association of Dining Companionship with Energy and Nutrient Intake Among Community-Dwelling Japanese Older Adults
Background: Community-dwelling older adults are at risk of malnutrition due to age-related declines in energy and nutrient intake. While the positive effect of dining companions on energy and nutrient intake has been suggested, evidence remains inconclusive. This study investigated the association between the number of dining companions and energy and nutrient intake, as well as the contribution of specific food groups to higher intake in the presence of dining companions. Methods: This cross-sectional study included 2865 community-dwelling older adults. The number of dining companions was assessed through self-administered questionnaires and categorized into three groups (none, 1, ≥2). Dietary intake was evaluated using a validated food frequency questionnaire, and multivariable regression analyses were conducted to control for potential confounders. Results: Participants dining with two or more companions consumed significantly more energy (β 143.85; 95% CI: 30.05, 257.65; p for trend = 0.01), protein (β 6.32; 95% CI: 1.05, 11.59), fat (β 6.78; 95% CI: 2.44, 11.12; p for trend = 0.002), and carbohydrates (β 17.43; 95% CI: 1.48, 33.37; p for trend = 0.06) compared to those dining alone. They also consumed higher amounts of rice, fats and oils, meat, other vegetables, fruits, and mushrooms. Conclusions: Dining with two or more companions is associated with greater energy and nutrient intake, particularly from energy- and nutrient-dense foods. Encouraging shared meals could serve as a potential approach to support dietary quality and address risks of malnutrition in older adults.
Open AccessThe Association of Dining Companionship with Energy and Nutrient Intake Among Community-Dwelling Japanese Older Adults
Background: Community-dwelling older adults are at risk of malnutrition due to age-related declines in energy and nutrient intake. While the positive effect of dining companions on energy and nutrient intake has been suggested, evidence remains inconclusive. This study investigated the association between the number of dining companions and energy and nutrient intake, as well as the contribution of specific food groups to higher intake in the presence of dining companions. Methods: This cross-sectional study included 2865 community-dwelling older adults. The number of dining companions was assessed through self-administered questionnaires and categorized into three groups (none, 1, ≥2). Dietary intake was evaluated using a validated food frequency questionnaire, and multivariable regression analyses were conducted to control for potential confounders. Results: Participants dining with two or more companions consumed significantly more energy (β 143.85; 95% CI: 30.05, 257.65; p for trend = 0.01), protein (β 6.32; 95% CI: 1.05, 11.59), fat (β 6.78; 95% CI: 2.44, 11.12; p for trend = 0.002), and carbohydrates (β 17.43; 95% CI: 1.48, 33.37; p for trend = 0.06) compared to those dining alone. They also consumed higher amounts of rice, fats and oils, meat, other vegetables, fruits, and mushrooms. Conclusions: Dining with two or more companions is associated with greater energy and nutrient intake, particularly from energy- and nutrient-dense foods. Encouraging shared meals could serve as a potential approach to support dietary quality and address risks of malnutrition in older adults.
- Open Access
- 24 December 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 849
A multi-center, open-label, randomized clinical trial evaluating the preventive effect of perampanel on craniotomy-induced epileptogenesis in seizure-naive patients with supratentorial brain tumors: study protocol for a GRAMPAS trial
BackgroundEarly seizures after craniotomy are significant perioperative complications that can adversely impact patient outcomes. Despite current guidelines advising against the routine use of antiseizure drugs for seizure after craniotomy prevention due to limited efficacy data, many clinicians continue prescribing them. This discrepancy highlights the need for robust evidence to guide clinical practice. This multi-center, randomized clinical trial was designed to investigate the efficacy of perampanel in preventing early seizures after craniotomy.MethodThis multi-center, open-label, randomized clinical trial will be conducted across five hospitals in Nagoya, Japan, from February 2024 to December 2026. A total of 142 seizure-naive patients with supratentorial brain tumors will be recruited and randomized (1:1) into the treatment and control groups. The treatment group will receive 2 mg of perampanel starting 2 days preoperatively and continuing for 28 days postoperatively, while the control group will receive no antiseizure drugs. The primary outcome is the incidence of seizures within 28 days after craniotomy. Secondary outcomes are length of hospital and intensive care unit stays and postoperative complications.DiscussionThis study addresses the critical need for evidence-based recommendations regarding antiseizure drug use for preventing early seizures after craniotomy. As the first multi-center, randomized trial evaluating perampanel's efficacy in this setting, the findings may significantly influence clinical guidelines and perioperative practices.Trial registrationThis trial was registered with the Japan Registry of Clinical Trials (approval number: jRCTs041230117) on December 18, 2023, a member of the Primary Registry Network of the World Health Organization's International Clinical Trials Registry Platform.
- 24 December 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 849
Open AccessA multi-center, open-label, randomized clinical trial evaluating the preventive effect of perampanel on craniotomy-induced epileptogenesis in seizure-naive patients with supratentorial brain tumors: study protocol for a GRAMPAS trial
BackgroundEarly seizures after craniotomy are significant perioperative complications that can adversely impact patient outcomes. Despite current guidelines advising against the routine use of antiseizure drugs for seizure after craniotomy prevention due to limited efficacy data, many clinicians continue prescribing them. This discrepancy highlights the need for robust evidence to guide clinical practice. This multi-center, randomized clinical trial was designed to investigate the efficacy of perampanel in preventing early seizures after craniotomy.MethodThis multi-center, open-label, randomized clinical trial will be conducted across five hospitals in Nagoya, Japan, from February 2024 to December 2026. A total of 142 seizure-naive patients with supratentorial brain tumors will be recruited and randomized (1:1) into the treatment and control groups. The treatment group will receive 2 mg of perampanel starting 2 days preoperatively and continuing for 28 days postoperatively, while the control group will receive no antiseizure drugs. The primary outcome is the incidence of seizures within 28 days after craniotomy. Secondary outcomes are length of hospital and intensive care unit stays and postoperative complications.DiscussionThis study addresses the critical need for evidence-based recommendations regarding antiseizure drug use for preventing early seizures after craniotomy. As the first multi-center, randomized trial evaluating perampanel's efficacy in this setting, the findings may significantly influence clinical guidelines and perioperative practices.Trial registrationThis trial was registered with the Japan Registry of Clinical Trials (approval number: jRCTs041230117) on December 18, 2023, a member of the Primary Registry Network of the World Health Organization's International Clinical Trials Registry Platform.
- Open Access
- 11 December 2024
- Published by MDPI AG in Preprints.org
The Association of Dining Companionship with Energy and Nutrient Intake Among Community-Dwelling Japanese Older Adults
Background: Community-dwelling older adults are at risk of malnutrition due to age-related declines in energy and nutrient intakes. While the positive effect of dining companions on energy and nutrient intake has been suggested, evidence remains inconclusive. This study investigated the association between the number of dining companions and energy and nutrient intakes, as well as the contribution of specific food groups to higher intakes in the presence of dining companions. Methods: This cross-sectional study included 2,865 community-dwelling older adults. The number of dining companions was assessed through self-administered questionnaires and categorized into three groups (none, 1, ≥2). Dietary intake was evaluated using a validated food frequency questionnaire, and multivariable regression analyses were conducted to control for potential confounders. Results: Participants dining with two or more companions consumed significantly more energy (β 143.85; 95% CI: 30.05, 257.65; P for trend= 0.01), protein (β 6.32; 95% CI: 1.05, 11.59), fat (β 6.78; 95% CI: 2.44, 11.12; P for trend = 0.002), and carbohydrates (β 17.43; 95% CI: 1.48, 33.37; P for trend = 0.06) compared to those dining alone. They also consumed higher amounts of rice, fats and oils, meat, other vegetables, fruits, and mushrooms. Conclusions: Dining with two or more companions is associated with greater energy and nutrient intakes, particularly from energy- and nutrient-dense foods. Encouraging shared meals could serve as a potential approach to support dietary quality and address risks of malnutrition in older adults.
- 11 December 2024
- Published by MDPI AG in Preprints.org
Open AccessThe Association of Dining Companionship with Energy and Nutrient Intake Among Community-Dwelling Japanese Older Adults
Background: Community-dwelling older adults are at risk of malnutrition due to age-related declines in energy and nutrient intakes. While the positive effect of dining companions on energy and nutrient intake has been suggested, evidence remains inconclusive. This study investigated the association between the number of dining companions and energy and nutrient intakes, as well as the contribution of specific food groups to higher intakes in the presence of dining companions. Methods: This cross-sectional study included 2,865 community-dwelling older adults. The number of dining companions was assessed through self-administered questionnaires and categorized into three groups (none, 1, ≥2). Dietary intake was evaluated using a validated food frequency questionnaire, and multivariable regression analyses were conducted to control for potential confounders. Results: Participants dining with two or more companions consumed significantly more energy (β 143.85; 95% CI: 30.05, 257.65; P for trend= 0.01), protein (β 6.32; 95% CI: 1.05, 11.59), fat (β 6.78; 95% CI: 2.44, 11.12; P for trend = 0.002), and carbohydrates (β 17.43; 95% CI: 1.48, 33.37; P for trend = 0.06) compared to those dining alone. They also consumed higher amounts of rice, fats and oils, meat, other vegetables, fruits, and mushrooms. Conclusions: Dining with two or more companions is associated with greater energy and nutrient intakes, particularly from energy- and nutrient-dense foods. Encouraging shared meals could serve as a potential approach to support dietary quality and address risks of malnutrition in older adults.
- Open Access
- 14 October 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (11) , 1053-1066
Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)
Hypoxic–ischemic encephalopathy (HIE), associated with high mortality and neurological sequelae, lacks established treatment except therapeutic hypothermia. Clinical-grade multilineage-differentiating stress-enduring (Muse) cells (CL2020) demonstrated safety and efficacy in nonclinical HIE rat models, thereby leading to an investigator-initiated clinical trial to evaluate CL2020 safety and tolerability in neonatal HIE as a single-center open-label dose-escalation study with 9 neonates with moderate-to-severe HIE who received therapeutic hypothermia. Each patient received a single intravenous injection of CL2020 cells between 5 and 14 days of age. The low-dose (3 patients) and high-dose (6 patients) groups received 1.5 × 106 and 1.5 × 107 cells/dose, respectively. The occurrence of any adverse event within 12 weeks following CL2020 administration was the primary endpoint of this trial. No significant changes in physiological signs including heart rate, blood pressure, and oxygen saturation were observed during or after administration. The only adverse event that may be related to cell administration was a mild γ-glutamyltransferase level elevation in one neonate, which spontaneously resolved without any treatment. All patients enrolled in the trial survived, and normal developmental quotients (≥ 85) in all 3 domains of the Kyoto Scale of Psychological Development 2001 were observed in 67% of the patients in this trial. CL2020 administration was demonstrated to be safe and tolerable for neonates with HIE. Considering the small number of patients, a randomized controlled confirmatory study is warranted to verify these preliminary findings and evaluate the efficacy of this therapy.
- 14 October 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (11) , 1053-1066
Open AccessSafety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)
Hypoxic–ischemic encephalopathy (HIE), associated with high mortality and neurological sequelae, lacks established treatment except therapeutic hypothermia. Clinical-grade multilineage-differentiating stress-enduring (Muse) cells (CL2020) demonstrated safety and efficacy in nonclinical HIE rat models, thereby leading to an investigator-initiated clinical trial to evaluate CL2020 safety and tolerability in neonatal HIE as a single-center open-label dose-escalation study with 9 neonates with moderate-to-severe HIE who received therapeutic hypothermia. Each patient received a single intravenous injection of CL2020 cells between 5 and 14 days of age. The low-dose (3 patients) and high-dose (6 patients) groups received 1.5 × 106 and 1.5 × 107 cells/dose, respectively. The occurrence of any adverse event within 12 weeks following CL2020 administration was the primary endpoint of this trial. No significant changes in physiological signs including heart rate, blood pressure, and oxygen saturation were observed during or after administration. The only adverse event that may be related to cell administration was a mild γ-glutamyltransferase level elevation in one neonate, which spontaneously resolved without any treatment. All patients enrolled in the trial survived, and normal developmental quotients (≥ 85) in all 3 domains of the Kyoto Scale of Psychological Development 2001 were observed in 67% of the patients in this trial. CL2020 administration was demonstrated to be safe and tolerable for neonates with HIE. Considering the small number of patients, a randomized controlled confirmatory study is warranted to verify these preliminary findings and evaluate the efficacy of this therapy.
- Open Access
- 3 August 2024
- Published by Elsevier in Lung Cancer
- Vol. 195, 107917
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer
- 3 August 2024
- Published by Elsevier in Lung Cancer
- Vol. 195, 107917
Open AccessMechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer
- 16 April 2024
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 34 (5) , 418-426
Clinical Impact of Malnutrition According to the Global Leadership Initiative on Malnutrition Criteria Combined With Kidney Dysfunction to Determine Mortality in Inpatients
- 16 April 2024
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 34 (5) , 418-426
Clinical Impact of Malnutrition According to the Global Leadership Initiative on Malnutrition Criteria Combined With Kidney Dysfunction to Determine Mortality in Inpatients
- Open Access
- 1 March 2024
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 16, 291-303
Assessing the Real-World, Long-Term Impact of Lemborexant on Sleep Quality in a Home-Based Clinical Study
Purpose: Both subjective and objective evaluations are essential for the treatment of insomnia. Lemborexant has been shown to be effective in the long-term based solely on a subjective basis, and no long-term objective measures have been evaluated under natural sleep conditions. Small, lightweight sleep electroencephalogram (EEG) monitor was used, instead of polysomnography, to objectively evaluate sleep at home 4 and 12 weeks after lemborexant treatment. Patients and Methods: Adults and elderly subjects with insomnia disorder, per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, were enrolled in this open-label, single-arm, single-center trial. Objective and subjective measures of sleep were prospectively assessed. Sleep disturbance, excessive sleepiness, and depressive symptoms were assessed using questionnaires. Results: A total of 45 subjects were screened, of which 33 were enrolled. Paired t-tests were conducted to evaluate changes in sleep variables and compared with the baseline; subjects showed significant improvements in objective sleep efficiency (SE) and subjective sleep parameters at weeks 4 and 12 following treatment with lemborexant. When baseline values were taken into account, a repeated-multivariate analysis of variance (MANOVA) revealed statistically significant changes in the objective measures. Sleep disturbance, excessive sleepiness, and depressive symptoms improved after three months of lemborexant treatment. Conclusion: Furthermore, lemborexant therapy improved nocturnal sleep, when measured objectively using sleep EEG monitoring at home, and improved daytime sleepiness and depressive symptoms in older adults with insomnia disorder.
- 1 March 2024
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 16, 291-303
Open AccessAssessing the Real-World, Long-Term Impact of Lemborexant on Sleep Quality in a Home-Based Clinical Study
Purpose: Both subjective and objective evaluations are essential for the treatment of insomnia. Lemborexant has been shown to be effective in the long-term based solely on a subjective basis, and no long-term objective measures have been evaluated under natural sleep conditions. Small, lightweight sleep electroencephalogram (EEG) monitor was used, instead of polysomnography, to objectively evaluate sleep at home 4 and 12 weeks after lemborexant treatment. Patients and Methods: Adults and elderly subjects with insomnia disorder, per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, were enrolled in this open-label, single-arm, single-center trial. Objective and subjective measures of sleep were prospectively assessed. Sleep disturbance, excessive sleepiness, and depressive symptoms were assessed using questionnaires. Results: A total of 45 subjects were screened, of which 33 were enrolled. Paired t-tests were conducted to evaluate changes in sleep variables and compared with the baseline; subjects showed significant improvements in objective sleep efficiency (SE) and subjective sleep parameters at weeks 4 and 12 following treatment with lemborexant. When baseline values were taken into account, a repeated-multivariate analysis of variance (MANOVA) revealed statistically significant changes in the objective measures. Sleep disturbance, excessive sleepiness, and depressive symptoms improved after three months of lemborexant treatment. Conclusion: Furthermore, lemborexant therapy improved nocturnal sleep, when measured objectively using sleep EEG monitoring at home, and improved daytime sleepiness and depressive symptoms in older adults with insomnia disorder.